Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NSAID Alzheimer’s Risk-Reduction Effects May Vary By Age – Study

This article was originally published in The Tan Sheet

Executive Summary

The apparent effect of non-steroidal anti-inflammatory drugs in reducing the risk of Alzheimer's disease may depend, in part, on a subject's age, Johns Hopkins University researchers suggest in the Sept. 24 issue of Neurology

You may also be interested in...



Aspirin, NSAID GI Bleeding Language Could Replace Alcohol Warning

Warnings detailing the risk of gastrointestinal bleeding with use of aspirin and other non-steroidal anti-inflammatory drugs should replace the current alcohol warning on such products, NDAC members asserted during a meeting in Silver Spring, Md. Sept. 20

NIA Aleve Vs. Vioxx Alzheimer's Study To Produce Data By 2002

A National Institute on Aging study comparing Bayer's OTC Aleve and Merck's Rx Vioxx in Alzheimer's patients will produce data in two and a half years.

NSAID use lowers relative risk of developing Alzheimer's -- NIA prospective study.

NSAID USE LOWERS RELATIVE RISK OF ALZHEIMER's DISEASE among participants of the National Institute on Aging's Baltimore Longitudinal Study of Aging. The study followed 1,686 participants from 1980 to 1995, comparing risks of developing Alzheimer's disease in users of aspirin or other nonsteroidal anti-inflammatory drugs and users of acetaminophen. A report on the study by Walter Stewart, PhD, Johns Hopkins, et al., is published in the March issue of Neurology.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel